Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables (2023 - 2025)

Historic Receivables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $5.1 million.

  • Tonix Pharmaceuticals Holding's Receivables fell 1624.92% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 1624.92%. This contributed to the annual value of $4.6 million for FY2024, which is 321.5% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Receivables stood at $5.1 million for Q3 2025, which was down 1624.92% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Receivables registered a high of $9.2 million during Q4 2023, and its lowest value of $2.3 million during Q3 2023.
  • Its 3-year average for Receivables is $5.0 million, with a median of $4.6 million in 2024.
  • Data for Tonix Pharmaceuticals Holding's Receivables shows a peak YoY increase of 16500.0% (in 2024) and a maximum YoY decrease of 4949.89% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Receivables stood at $9.2 million in 2023, then crashed by 49.5% to $4.6 million in 2024, then increased by 11.07% to $5.1 million in 2025.
  • Its Receivables stands at $5.1 million for Q3 2025, versus $4.3 million for Q2 2025 and $4.6 million for Q1 2025.